According to the research report, the global hepatitis B market size is expected to touch USD 6.45 Billion by 2032, from USD 4.47 Billion in 2022, growing with a significant CAGR of 3.37% from 2023 to 2032. 

The report offers intricate dynamics about different aspects of the global hepatitis B market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global hepatitis B during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/2813

Report Scope of the Hepatitis B Market:

This study covers a detailed segmentation of the global hepatitis B market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global hepatitis B market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

• Accord Healthcare Inc.
• Apotex Corp.
• Arbutus Biopharma
• Arrowhead Pharma
• Aurobindo Pharma Limited
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• GlaxoSmithKline
• Lupin Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Par Pharmaceutical, Inc.
• Teva Pharmaceuticals
• Zydus Pharmaceuticals

Market Segmentation

By Type

• Acute
• Chronic

By Treatment

• Immune Modulator Drugs
  • Pegylated Interferon
  • Interferon Alpha
• Antiviral Drugs
  • Tenofovir disoproxil
  • Entecavir
  • Telbivudine
  • Lamivudine
  • Others
• Vaccine
• Surgery (Liver Transplant)

By Distribution Channel

• Hospital & Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Research Methodology

The research methodology adopted by analysts for compiling the global hepatitis B report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global hepatitis B market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Hepatitis B Market 

5.1. COVID-19 Landscape: Hepatitis B Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Hepatitis B Market, By Type

8.1. Hepatitis B Market, by Type, 2023-2032

8.1.1 Acute

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Chronic

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Hepatitis B Market, By Treatment

9.1. Hepatitis B Market, by Treatment, 2023-2032

9.1.1. Immune Modulator Drugs

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Antiviral Drugs

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Vaccine

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Surgery (Liver Transplant)

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Hepatitis B Market, By Distribution Channel

10.1. Hepatitis B Market, by March, 2023-2032

10.1.1. Hospital & Retail Pharmacies

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Online Pharmacies

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Hepatitis B Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2020-2032)

11.1.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.1.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.2.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.3.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.4.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.5.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.5.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Treatment (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel(2020-2032)

Chapter 12. Company Profiles

12.1. Accord Healthcare Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Apotex Corp.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Arbutus Biopharma

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Arrowhead Pharma

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Aurobindo Pharma Limited

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bristol-Myers Squibb Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Gilead Sciences, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. GlaxoSmithKline

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Lupin Pharmaceuticals, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Merck & Co., Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: [email protected]

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com